JP5490346B2 - ４−ヒドロキシタモキシフェンによる乳癌の予防および治療 - Google Patents

４−ヒドロキシタモキシフェンによる乳癌の予防および治療 Download PDF

Info

Publication number
JP5490346B2
JP5490346B2 JP2004570040A JP2004570040A JP5490346B2 JP 5490346 B2 JP5490346 B2 JP 5490346B2 JP 2004570040 A JP2004570040 A JP 2004570040A JP 2004570040 A JP2004570040 A JP 2004570040A JP 5490346 B2 JP5490346 B2 JP 5490346B2
Authority
JP
Japan
Prior art keywords
hydroxy tamoxifen
tamoxifen
breast
breast cancer
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004570040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514967A5 (enExample
JP2006514967A (ja
Inventor
ドミニク サラン−ドルーアン、
ジャック ウェピエール、
フィリップ ルアネ、
Original Assignee
ブザン ヘルスケア ルクセンブルグ エスアーエールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ブザン ヘルスケア ルクセンブルグ エスアーエールエル filed Critical ブザン ヘルスケア ルクセンブルグ エスアーエールエル
Publication of JP2006514967A publication Critical patent/JP2006514967A/ja
Publication of JP2006514967A5 publication Critical patent/JP2006514967A5/ja
Application granted granted Critical
Publication of JP5490346B2 publication Critical patent/JP5490346B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2004570040A 2003-04-01 2003-12-15 ４−ヒドロキシタモキシフェンによる乳癌の予防および治療 Expired - Lifetime JP5490346B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45896303P 2003-04-01 2003-04-01
US60/458,963 2003-04-01
PCT/EP2003/015029 WO2004087123A1 (en) 2003-04-01 2003-12-15 Prevention and treatment of breast cancer with 4-hydroxy tamoxifen

Publications (3)

Publication Number Publication Date
JP2006514967A JP2006514967A (ja) 2006-05-18
JP2006514967A5 JP2006514967A5 (enExample) 2007-02-08
JP5490346B2 true JP5490346B2 (ja) 2014-05-14

Family

ID=33131847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004570040A Expired - Lifetime JP5490346B2 (ja) 2003-04-01 2003-12-15 ４−ヒドロキシタモキシフェンによる乳癌の予防および治療

Country Status (11)

Country Link
US (2) US7704516B2 (enExample)
EP (3) EP1608353B1 (enExample)
JP (1) JP5490346B2 (enExample)
AU (1) AU2003294973B2 (enExample)
CA (1) CA2519980C (enExample)
ES (3) ES2483896T3 (enExample)
IL (1) IL170807A (enExample)
MX (1) MXPA05010597A (enExample)
NO (1) NO333805B1 (enExample)
NZ (1) NZ542499A (enExample)
WO (1) WO2004087123A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327363D1 (de) * 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
WO2004087123A1 (en) * 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
ES2304610T3 (es) * 2003-06-09 2008-10-16 Ascend Therapeutics, Inc. Tratamiento y prevencion de cicatrizacion excesiva con 4-hidroxi-tamoxifeno.
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) * 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) * 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
MXPA06010914A (es) * 2004-03-22 2006-12-15 Besins Int Lab Tratamiento y prevencion de enfermedades de mama benigna con 4-hidroxi tamoxifen.
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
GEP20104889B (en) * 2004-10-14 2010-02-10 Laboratoires Besins Int 4-hydroxy tamoxifen gel formulations
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) * 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
EP3143392B1 (en) * 2014-05-12 2023-02-22 Quest Diagnostics Investments Incorporated Quantitation of tamoxifen metabolites by mass spectrometry
KR101571098B1 (ko) 2014-07-16 2015-11-23 건국대학교 산학협력단 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물
EP3230478B1 (en) * 2014-12-12 2023-08-02 Miradx Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors
CA3022377A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Targeted measure of transcriptional activity related to hormone receptors
KR20200052349A (ko) 2017-09-11 2020-05-14 아토사 테라퓨틱스, 인크. 엔독시펜을 제조 및 사용하는 방법
WO2020023616A1 (en) * 2018-07-24 2020-01-30 Cornell University Methods of upregulating tiparp as anticancer strategies
US12201591B2 (en) 2019-07-03 2025-01-21 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
WO2025019830A1 (en) * 2023-07-19 2025-01-23 Atossa Therapeutics, Inc. Anti-tumor compounds and methods of use thereof and synthesis thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP0287690B1 (de) * 1987-04-21 1992-09-02 HEUMANN PHARMA GMBH & CO Stabile Lösungsmitteladdukte von Z-1-(p-beta-Dimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl)-2-phenylbut-1-en
US5045553A (en) 1987-06-24 1991-09-03 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
TW218849B (enExample) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4407742C1 (de) 1994-03-08 1995-06-22 Hexal Pharma Gmbh Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
US5720963A (en) * 1994-08-26 1998-02-24 Mary Kay Inc. Barrier disruption treatments for structurally deteriorated skin
ATE200978T1 (de) 1996-03-29 2001-05-15 S W Patentverwertungs Ges M B KOSMETIKUM BZW. KOSMETIKZUSAMMENSETZUNG ZUR GLÄTTUNG UND STRAFFUNG DER HAUT BEI GESTÖRTEM UNTERHAUT-BINDE-FETTGEWEBE, INSBESONDERE BEI DER ßCELLULITEß
JP2001527037A (ja) 1997-12-23 2001-12-25 ヘキサル アーゲー Ｚ−４−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
ATE290856T1 (de) 1999-12-16 2005-04-15 Dermatrends Inc Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
DE10033853A1 (de) 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
PT1317921E (pt) 2001-12-07 2009-11-06 Besins Mfg Belgium Composição farmacêutica sob a forma de gel ou de solução à base de di-hidrotestosterona, seu processo de preparação e suas utilizações
WO2004087123A1 (en) 2003-04-01 2004-10-14 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
ATE324880T1 (de) * 2002-12-18 2006-06-15 Besins Int Lab Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE60327363D1 (de) 2002-12-18 2009-06-04 Besins Int Lab Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
ES2304610T3 (es) 2003-06-09 2008-10-16 Ascend Therapeutics, Inc. Tratamiento y prevencion de cicatrizacion excesiva con 4-hidroxi-tamoxifeno.
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US7507769B2 (en) 2004-03-22 2009-03-24 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1579856A1 (en) 2004-03-22 2005-09-28 Laboratoires Besins International Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
US20050208139A1 (en) 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
EP1647271A1 (en) 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations

Also Published As

Publication number Publication date
US7704516B2 (en) 2010-04-27
EP1608353B1 (en) 2014-04-30
US20090186944A1 (en) 2009-07-23
EP1952810A1 (en) 2008-08-06
MXPA05010597A (es) 2006-03-09
HK1119950A1 (en) 2009-03-20
AU2003294973B2 (en) 2010-05-13
US20050031695A1 (en) 2005-02-10
EP1608353A1 (en) 2005-12-28
JP2006514967A (ja) 2006-05-18
EP1941871B1 (en) 2014-01-08
AU2003294973A1 (en) 2004-10-25
CA2519980C (en) 2012-04-10
HK1086193A1 (en) 2006-09-15
EP1952810B1 (en) 2014-01-08
NZ542499A (en) 2008-10-31
IL170807A (en) 2014-08-31
NO333805B1 (no) 2013-09-16
US8475814B2 (en) 2013-07-02
ES2456958T3 (es) 2014-04-24
ES2456957T3 (es) 2014-04-24
CA2519980A1 (en) 2004-10-14
WO2004087123A1 (en) 2004-10-14
NO20054526L (no) 2005-09-30
EP1941871A1 (en) 2008-07-09
ES2483896T3 (es) 2014-08-08

Similar Documents

Publication Publication Date Title
JP5490346B2 (ja) ４−ヒドロキシタモキシフェンによる乳癌の予防および治療
JP4684655B2 (ja) ４−ヒドロキシタモキシフェンによる乳房密度低下
JP4938237B2 (ja) ４−ヒドロキシタモキシフェンによる乳房痛の治療
EP1579856A1 (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
JP5072588B2 (ja) ４−ヒドロキシタモキシフェンを用いた良性乳房疾患の治療および予防
NZ547744A (en) Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
HK1119950B (en) Formulations for prevention and treatment of breast cancer with 4-hydroxy tamoxifen
HK1086193B (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
HK1120228A (en) Formulations for the reduction of breast density with 4-hydroxy tamoxifen
HK1130435B (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1077512B (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1130435A (en) Reduction of breast density with 4-hydroxy tamoxifen
HK1079453A (en) Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100519

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100921

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110817

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140226

R150 Certificate of patent or registration of utility model

Ref document number: 5490346

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term